Clinical trials are experiments designed to test the safety and efficacy of new treatments or interventions in a controlled setting. The results of these trials are used to make decisions about whether or not to approve new drugs or treatments for use in the general population.
However, it’s important to recognize that the results of clinical trials may have limitations when it comes to their generalizability to the larger population. This is because clinical trials are typically conducted under controlled conditions, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.
Some of the limitations of clinical trial results in terms of generalizability to the larger population include:
Limited patient population: Clinical trials often have strict inclusion and exclusion criteria, which can limit the types of patients who are eligible to participate. This means that the results may not be generalizable to patients who do not meet these criteria.
Short follow-up time: Clinical trials are often conducted over a relatively short period of time, which may not be long enough to capture the long-term effects of the treatment or intervention.
Controlled setting: Clinical trials are conducted in a controlled setting, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.
Selective reporting [Controversial]: Clinical trial results may be subject to selective reporting, where only the most favorable outcomes are reported, while negative results are suppressed.
Real-world evidence (RWE) refers to data collected outside of clinical trials, such as data from electronic health records, insurance claims, and patient registries. RWE can provide important insights into how treatments or interventions work in real-world settings, and can help to address some of the limitations of clinical trial results in terms of generalizability.
However, it’s important to recognize that RWE also has its own limitations, such as the potential for confounding and bias, as well as issues related to data quality and completeness. Therefore, it’s important to carefully consider the limitations and potential biases of both clinical trial results and real-world evidence when making decisions about treatments or interventions for the larger population.
Share this story...
Real World Evidence (RWE) 101 – SOPs and Regional Regulations
RWE 101 - SOPs and Regional Regulations In the realm of quality assurance (QA), it's vital that standard operating procedures (SOPs) are crafted in a way that accurately and [...]
Real World Evidence (RWE) 101 – Standard Operating Procedures
RWE 101 - Standard Operating Procedures Standard Operating Procedures (SOPs) are critical for the operation of any business, particularly in regulated industries like pharmaceuticals where precision, safety, and compliance [...]
Real World Evidence (RWE) 101 – Publications
RWE 101 - Publications The term RWE stands for Real-World Evidence, which is evidence derived from real-world data (RWD). RWD are data relating to patient health status and/or the [...]
Real World Evidence (RWE) 101 – Archiving Specifics
RWE 101 - Archiving Specifics Proper archiving of clinical study documents is an important practice for maintaining the quality, integrity, and usability of study data, and for ensuring regulatory [...]
Real World Evidence (RWE) 101 – Archiving Generics
RWE 101 - Archiving Generics In the context of health research, both observational studies and clinical trials are crucial for understanding disease processes, patient outcomes, and the safety and [...]
Real World Evidence (RWE) 101 – Study Close-out
RWE 101 - Study Close-Out Closing out an observational study involves several key steps to ensure that all study activities are concluded properly, and data integrity is maintained. Here [...]







